LifeStance Health Group, Inc. (NASDAQ:LFST) Sees Significant Decline in Short Interest

LifeStance Health Group, Inc. (NASDAQ:LFST) was the recipient of a large decrease in short interest in December. As of December 31st, there was short interest totalling 9,860,000 shares, a decrease of 10.1% from the December 15th total of 10,970,000 shares. Approximately 8.9% of the company’s stock are short sold. Based on an average trading volume of 1,460,000 shares, the days-to-cover ratio is presently 6.8 days.

LifeStance Health Group Trading Up 0.1 %

LFST stock opened at $7.99 on Friday. The company has a market capitalization of $3.06 billion, a PE ratio of -30.73 and a beta of 1.26. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.32 and a current ratio of 1.32. LifeStance Health Group has a one year low of $4.64 and a one year high of $9.20. The company’s 50 day moving average price is $7.44 and its two-hundred day moving average price is $6.72.

LifeStance Health Group (NASDAQ:LFST) last issued its earnings results on Thursday, November 7th. The company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.05. The company had revenue of $312.70 million for the quarter, compared to analysts’ expectations of $302.25 million. LifeStance Health Group had a negative net margin of 7.90% and a negative return on equity of 6.66%. The firm’s revenue was up 18.9% compared to the same quarter last year. During the same quarter last year, the company earned ($0.17) EPS. As a group, analysts predict that LifeStance Health Group will post -0.2 earnings per share for the current fiscal year.

Insider Transactions at LifeStance Health Group

In related news, Director Robert Bessler sold 75,000 shares of the stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $7.54, for a total transaction of $565,500.00. Following the completion of the sale, the director now directly owns 1,424,447 shares of the company’s stock, valued at approximately $10,740,330.38. This trade represents a 5.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 6.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC grew its stake in shares of LifeStance Health Group by 65.7% in the fourth quarter. SG Americas Securities LLC now owns 90,355 shares of the company’s stock worth $666,000 after purchasing an additional 35,823 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in LifeStance Health Group by 13.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 94,636 shares of the company’s stock worth $662,000 after buying an additional 10,894 shares during the period. Principal Financial Group Inc. grew its position in shares of LifeStance Health Group by 6.1% in the 3rd quarter. Principal Financial Group Inc. now owns 4,116,766 shares of the company’s stock worth $28,817,000 after buying an additional 235,316 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of LifeStance Health Group by 26.8% during the third quarter. Geode Capital Management LLC now owns 3,452,178 shares of the company’s stock valued at $24,170,000 after buying an additional 729,794 shares during the period. Finally, Wellington Management Group LLP increased its stake in shares of LifeStance Health Group by 15.2% during the third quarter. Wellington Management Group LLP now owns 4,830,441 shares of the company’s stock valued at $33,813,000 after buying an additional 638,385 shares during the period. 85.50% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

LFST has been the subject of a number of research reports. The Goldman Sachs Group raised shares of LifeStance Health Group from a “neutral” rating to a “buy” rating and set a $10.00 target price for the company in a research report on Monday, December 16th. Barclays raised their target price on LifeStance Health Group from $6.00 to $7.00 and gave the stock an “underweight” rating in a research report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, LifeStance Health Group currently has an average rating of “Hold” and a consensus target price of $8.70.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.